Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Serum concentrations of per- and polyfluoroalkyl substances and risk of ovarian cancer.

About this Publication
Title
Serum concentrations of per- and polyfluoroalkyl substances and risk of ovarian cancer.
Pubmed ID
40748719 (View this publication on the PubMed website)
Digital Object Identifier
Publication
J Natl Cancer Inst. 2025 Aug 1
Authors
Jones RR, Madrigal JM, Medgyesi DN, Fisher JA, Calafat AM, Botelho JC, Kato K, Albert PS, Silverman DT, Hofmann JN, Trabert B
Affiliations
  • Occupational & Environmental Epidemiology Branch (OEEB), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Rockville, Maryland, USA.
  • Organic Analytical Toxicology Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Biostatistics Branch, DCEG, NCI.
  • Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Abstract

BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are persistent, widespread environmental contaminants and some are endocrine-disrupting. Studies of gynecologic cancers are limited; we evaluated ovarian cancer, a rare, often fatal malignancy.

METHODS: This nested case-control study included 318 ovarian cancer cases and 472 individually matched female controls in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, which recruited participants aged 55-74 years from 10 U.S. study centers (1993-2001). We ascertained cases through 2016 and quantitated eight PFAS in prediagnostic serum samples. We estimated ORs and 95% CIs for continuous (log2-transformed) and categorized PFAS concentrations via conditional logistic regression models implicitly adjusting for matching factors (age, center, randomization year, year of blood draw, race and ethnicity) and adjusted for smoking, body mass index, family history of cancer, menopausal hormone therapy and oral contraceptive use, parity, and number of freeze-thaws.

RESULTS: We found a positive association with ovarian cancer for a doubling in 2-(N-methyl-perfluorooctane sulfonamido) acetic acid (MeFOSAA) concentrations (ORperlog2=1.24, CI = 1.03-1.49) and 62% greater risk among those in the highest quartile (ORQ4vsQ1=1.62, CI = 1.03-2.54; p-trend = 0.02). Perfluorooctane sulfonic acid (PFOS) was associated with increased risk (ORperlog2=1.47, CI = 1.05-2.06) with no quartile trend (p-trend = 0.79). Associations with perfluorononanoic (ORperlog2=1.36, CI = 0.95-1.95) and perfluorodecanoic acid (ORperlog2=1.35, CI = 0.94-1.95) were suggested, with non-monotonic quartile trends (p-trend = 0.12-0.21). MeFOSAA associations were strongest in women aged 55-59 (ORperlog2=1.60, CI = 1.13-2.27), more moderate in those 60-64 (ORperlog2=1.31, CI = 0.90-1.90) and null among women 65 + (ORperlog2=1.02, CI = 0.73-1.43; p-heterogeneity = 0.22). Associations persisted in cases diagnosed ≥8 years after blood collection.

CONCLUSIONS: These findings offer novel evidence for PFAS as ovarian cancer risk factors, particularly PFOS and MeFOSAA, a PFOS precursor.

Related CDAS Studies
Related CDAS Projects